In:
The Clinical Respiratory Journal, Wiley, Vol. 8, No. 2 ( 2014-04), p. 206-212
Abstract:
Sunitinib is an oral multitargeted tyrosine kinase inhibitor ( TKI ) exhibiting antiagiogenic and antitumor effects. Objective To evaluate the efficacy and potential toxicity of sunitinib therapy in advanced non‐small cell lung cancer ( NSCLC ) patients in China. Methods From J anuary 2009 to A ugust 2011, 30 patients with stage IV NSCLC , who were pretreated with the epidermal growth factor receptor ( EGFR )‐ TKI s and then received sunitinib, were retrospectively reviewed. Univariate and multivariate C ox proportional hazard regression analysis was performed to determine the potential prognostic risk factors influencing NSCLC survival. Results The median progression‐free survival ( PFS ) and median overall survival ( OS ) of all 30 treated patients was 1.25 months [95% confidence interval ( CI ): 0.90–1.9 months] and 3.40 months (95% CI : 3.00–6.80 months), respectively. C ox regression analysis suggested that E astern C ooperative O ncology G roup ( ECOG ) performance status ( PS ) is predictive of both PFS ( P = 0.001) and OS ( P 〈 0.001). Common adverse events ( AEs ) included hand‐foot syndrome (53.3%), mucositis (40.0%), rash (36.7%) and diarrhea (33.3%). Conclusion No sign of overall clinical benefits of sunitinib was detected in patients with pretreated EGFR ‐ TKI s. Most patients suffered AE s from mild to moderate severity. ECOG PS is highly associated with PFS and OS rate. Further studies in NSCLC are required to determine whether sunitinib is beneficial nor not.
Type of Medium:
Online Resource
ISSN:
1752-6981
,
1752-699X
DOI:
10.1111/crj.2014.8.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2442214-9
Permalink